190728-25-7

Basic information

• Product Name: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-
• Synonyms: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-;[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]amine;4-[(6,7-Dimethoxyquinolin-4-yl)oxy]aniline;6,7-Dimethoxy-4-(4-aminophenoxy)quinoline;BenzeMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-;4-[(6,7-diMethoxy-4-quinolinyl)oxy]-BenzenaMine;4-(2,3-dimethoxynaphthalen-5-yloxy)benzenamine;Intermediate 1 of Cabozantinib
• CAS NO: 190728-25-7
• Molecular Formula: C₁₇H₁₆N₂O₃
• Molecular Weight: 296.32054
• EINECS: -0
• Mol File: 190728-25-7.mol
• Article Data: 70

Chemical Properties

• Melting Point: 211.0 to 215.0 °C
• Boiling Point: 481.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.246±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 6.79±0.30(Predicted)
• CAS DataBase Reference: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-(190728-25-7)
• EPA Substance Registry System: BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]-(190728-25-7)

Safety Data

• Hazardous Substances Data: 190728-25-7(Hazardous Substances Data)

Usage

Uses

4-(6,7-Dimethoxy-Quinolin-4-Yloxy)-Phenylamine is used in preparation of Cabozantinib Defluorination impurity.

Upstream product

• 190728-24-6 6,7?dimethoxy?4?(4?nitrophenoxy)quinoline 
• 35654-56-9 6,7-dimethoxy-4-chloroquinoline 
• 123-30-8 4-amino-phenol 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 4101-32-0 4',5'-dimethoxy-2'-nitroacetophenone 
• 100-02-7 4-nitro-phenol 
• 350-46-9 4-Fluoronitrobenzene 
• 213699-53-7 5-(((3,4-dimethoxyphenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 14593-46-5 sodium tert-pentoxide 
• 13425-93-9 6,7-dimethoxyquinoline-4-ol 
• 4101-30-8 2-amino-4,5-dimethoxyacetophenone 
• 26893-22-1 1,4-Dihydro-6,7-dimethoxy-4-oxo-3-quinolinecarboxylic acid 
• 127285-54-5 1,4-dihydro-6,7-dimethoxy-4-oxoquinoline 

Relevant articles and documents

Crystal structures of intermediates in a new synthesis of antitumor drug cabozantinib

The heterocyclic antitumor drug cabozantinib was synthesized by condensation of 4-(6,7-dimethoxyquinolin-4-yloxy)aniline and methyl 1-(4-fluorophenylcarbamoyl)cyclopropanecarboxylate in the presence of two equivalents of sodium methoxide and azeotropic re

Synthesis method of cabozantinib and intermediate thereof

The invention provides a synthesis method of cabozantinib and an intermediate thereof, and belongs to the field of medicinal chemistry. According to the invention, cyclopropane-1,1-dicarboxylic acid amine is used as a key intermediate, and reacts with sub

PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF

Disclosed are a kinase inhibitor and a pharmaceutical composition comprising the kinase inhibitor. The kinase inhibitor comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug

COMPOUNDS AND METHODS OF USE

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.